Franklin Street Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Franklin Street Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-40,000	Closed	-$659K	–	201
2016 Q2	$659K	Buy	40,000 +20,000	+100%	+$324K	0.13%	118
2016 Q1	$331K	Hold	20,000	–	–	0.07%	167
2015 Q4	$433K	Hold	20,000	–	–	0.09%	150
2015 Q3	$396K	Buy	+20,000	New	+$632K	0.08%	154

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Franklin Street Advisors's HZNP Position: Q3 2016 in Review

Franklin Street Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2016, closing a stake of 40,000 shares — an estimated $659K sold.

Franklin Street Advisors first reported a position in HZNP in Q3 2015 and held it in 4 quarters. The position peaked at $659K in Q2 2016. 232 funds tracked by Wall St. Rank hold HZNP as of Q3 2016.

Franklin Street Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2016 after selling out during the quarter.
Franklin Street Advisors sold 40,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2016, an estimated $659K.
Franklin Street Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015 and held it in 4 quarters.
Franklin Street Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $659K in Q2 2016.
232 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2016.

Based on Franklin Street Advisors's 13F filing for Q3 2016, filed 5 Oct 2016.